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Abstract
Human immunodeficiency virus (HIV) is associated with neuroendocrine
dysfunction which may contribute to co-morbid stress-sensitive disorders. The
hypothalamic-pituitary-adrenal (HPA) and -gonadal (HPG) axes are perturbed
in up to 50% of HIV patients, but the mechanisms are not known, but we find
that transgenic expression of Tat protein to recapitulate the clinical phenotype
in male mice. We hypothesized that HPA and/or HPG dysregulation contributes
to Tat-mediated interactions with oxycodone, a clinically-used opioid often
prescribed to HIV patients. Mice that expressed the Tat1-86 protein [Tat(+) mice]
or their control counterparts that did not [Tat(-) control mice] were exposed to
forced swim stress (or not) and behaviorally-assessed for motor behavior in the
open field task. Mice were pretreated with vehicle, RU-486, or antalarmin to
block glucocorticoid receptors (GR) or CRF receptors (CRF-R), respectively
and some mice were ovariectomized. Circulating corticosterone was assessed
via enzyme-linked immunosorbant assay. In transgenic female mice, HIV Tat
elevated corticosterone levels recapitulating the clinical HIV phenotype. We
have found males to additionally express adrenal insufficiency in response to
Tat exposure, however, this was not observed in females. When challenged with
oxycodone, Tat-exposed females demonstrated a potentiated psychomotor
response that was not attenuated with via GR or CRF-R inhibition. However,
ovariectomy elevated hypothalamic allopregnanolone levels concurrent with
significant attenuation of the psychomotor response revealing gonadal
hormones for Tat-mediated potentiation of oxycodone. In the non-stressed or
stressed paradigm, either oxycodone-administered mice or diestrous mice
demonstrated a significant increase in hypothalamic allopregnanolone
indicative of central adaptive response to stress. Together, these effects support
the notion that Tat exposure dysregulates the HPA and HPG axes, potentially
raising vulnerability to stress-related substance use disorders in females. HPG
activation may be necessary for the combined oxycodone-Tat interaction
indicating the importance of maintained HPG feedback in this vulnerable
population.
Hypotheses
•In vivo, HIV-1 Tat and oxycodone will interact to potentiate
psychomotor behavior involving hypothalamic-pituitary-adrenal (HPA)
axis activation.
•HPA blockade by (Antalarmin or RU-486) or HPG blockade by OVX
may attenuate combined Tat and oxycodone psychomotor behavior and
restore HPA response.
•Exposure to Tat and/or oxycodone may increase central
Allopregnanolone levels.
Methods
Animal Subjects: Transgenic mice were bred in the vivarium at the University of
Mississippi (University, MS). Tat(+) mice expressed a Tat 1-86 protein that became
transcriptionally-active in the presence of doxycycline (induced via doxycycline
injection, 30mg/kg/d for 5d). Tat(-) mice expressed the transcription factor
necessary to activate transgene induction, but did not express the transgene itself.
Psychomotor and anxiogenic effects of Tat induction have been previously-
observed using these mice [1-3]. Mice were kept in a temperature- and humidity-
controlled environment on a 12:12 h light:dark cycle (lights off at 09:00 h) with
ad libitum access to food and water.
Estrous Cycle phase & Behavioral Assessment: Estrous cycle was determined via
vaginal lavage conducted daily. Mice were behaviorally-tested in proestrous and
diestrous cycle phase followed by swim stress challenge (stressed paradigm) or not
(non-stressed paradigm) and then assessed in an open field task. All tests were
completed within 14 days of doxycycline induction and occurred 2-3 h into the
dark phase of the light cycle. Data were encoded by an ANY-maze behavioral
tracking system (Stoelting Co., Wood Dale, IL). Some mice were ovariectomized
and allowed for 1 week for hormone washout followed by Tat induction and
behavior assessment.
Chemicals: Tat1-86 was induced in transgenic mice [Tat(+) or Tat(-)] via
doxycycline injection (30 mg/kg, i.p.; Cayman Chemical, Ann Arbor, MI).
Antalarmin (20 mg/kg, i.p.; 7 days Cayman Chemical, Ann Arbor, MI) and/or RU-
486 (20 mg/kg, i.p.; 8 days Cayman Chemical, Ann Arbor, MI).
Oxycodone (3 mg/kg, i.p.; Sigma‐Aldrich, MO, USA) or saline (0.9%) was
administered once 15 min prior to testing.
Enzyme-linked immunosorbent assay (ELISA): Circulating corticosterone was
assessed via ELISA kit per manufacturer instructions (Neogen Life Sciences).
Plates were read on a CLARIOstar microplate reader (BMG Labtech Inc., Cary,
NC).
Ultra Performance Liquid Chromatography (UPLC) ‐ Mass Spectrometry (MS):
Central Allopregnanolone levels were assessed via UPLC-MS per the standard
operating procedure.
HIV-1 Tat  promoted HPA dysregulation and potentiated Oxycodone-
mediated psychomotor behavior Summary
• Tat expression interacted with oxycodone to
potentiate psychostimulatory effects (Fig. 1B).
• When stressed, mice in diestrous phase traveled
significantly greater distance than their proestrous
counterparts (Fig. 1E).
• OVX significantly attenuated combined Tat and
oxycodone mediated psychomotor behavior (Fig.
1H)
• Tat expression and/or oxycodone exposure
increased circulating corticosterone at baseline
compared to proestrous Tat(-) controls,
recapitulating the clinical phenotype (Fig. 1C).
• When stressed, proestrous and/or oxycodone
exposure significantly produced higher circulating
corticosterone levels (Fig. 1F)
• Unlike males, adrenal insufficiency was not
observed in female mice, demonstrated by a
increase in circulating corticosterone levels in
Antalarmin, RU-486 or OVX group when
compared to vehicle controls (Fig. 1I).
• A significant increase in hypothalamic
allopregnanolone was observed when mice were
in diestrous phase and/or exposed to oxycodone.
(Fig. 1 D,G)
Conclusions
HIV Tat and clinical opioids can interact to 
activate stress pathways, influencing 
psychomotor behavior which may involve HPA 
axis dysregulation. OVX and not Antalarmin or 
RU-486 attenuated the psychomotor behavior 
implicating gonadal hormones as drivers for 
neuroHIV behavior in female mice. Thus, 
neuroendocrine axis may be an important target 
for combined HIV-1 Tat and opioid interactions 
within the HIV infected population.
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Figure 1: Tat1-86 was induced in Tat(+) and not induced in Tat(-) mice via doxycycline injection (30mg/kg for 5 d) . Saline or oxycodone (3mg/kg) were administered 15 minutes prior to behavior testing and
assessed in an open field (n = 8-10); (A) Behavior Timeline. Distance (m) traveled in open field after (n=8-10), Circulating corticosterone (ng/mL; n=7-10) and hypothalamic allopregnanolone (n=8
tissues/group) were assessed in Non-stressed (Acute administration of saline or oxycodone in panels B,C,D); Stressed (Exposure to forced swim stress stimuli followed by acute administration of saline or
oxycodone in panels E,F,G) and HPA/HPG Blockade (Administration of Vehicle, Antalarmin, RU-486 or OVX followed by administration of saline and oxycodone in panels H & I) and OVX (in panel J).
† indicates a main effect for oxycodone‐administered mice to differ from saline administered controls in panels B, E, F, H. § indicates an interaction wherein oxycodone‐administered Tat(+) mice differ from
respective Tat(-) controls and saline‐administered controls in panels B, E, H, ‡ indicates an interaction wherein oxycodone‐administered Tat(+) OVX mice differ from all other oxycodone‐ administered Tat(+)
groups in panel H, ^ indicates an interaction wherein the denoted group differs from all other groups in panel C, # indicates a main effect for proestrous mice to differ from diestrous mice in panel D, E, F, G.
@ indicates an interaction wherein the denoted group differs from their respective vehicle controls in panel I, ¶ indicates an interaction wherein mice pretreated with RU‐486 differ from all other groups in panel
I, § indicates an interaction wherein denoted group differs from Tat(-) or Tat(+) proestrous mice in panel D & G. ^ indicates an interaction wherein the denoted group differs from oxycodone-administered,
Tat(+) diestrous mice in panel G, p < 0.05.
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